Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background: Patients with major depressive disorder (MDD) having active suicidal ideation with intent require immediate treatment. Methods: This double-blind study (ASPIRE II) randomized adults (aged 18–64 years) with MDD having active suicidal ideation with intent to esketamine 84 mg or placebo nasal spray twice weekly for 4 weeks, given with comprehensive standard of care (hospitalization ≥5 days and newly initiated or optimized oral antidepressant[s]). Change from baseline to 24 hours post-first dose in Montgomery-Asberg Depression Rating Scale total score (primary efficacy endpoint) was analyzed using ANCOVA. Clinical Global Impression–Severity of Suicidality–revised (key secondary endpoint) was analyzed using ANCOVA on ranks of change. Results: Of 230 patients who were randomized (115 per arm), 227 received study drug and were included in efficacy/safety analyses; 184 (80.0%) completed double-blind treatment. Greater improvement in Montgomery-Asberg Depression Rating Scale total score was observed with esketamine (mean [SD]: –15.7 [11.56]) vs placebo (–12.4 [10.43]), each with standard of care, at 24 hours (least-squares mean difference [SE]: –3.9 [1.39], 95% CI: –6.60, –1.11; 2-sided P = .006). This was also noted at the earlier (4-hour) timepoint (least-squares mean difference –4.2, 95% CI: –6.38, –1.94). Patients in both treatment groups experienced rapid reduction in Clinical Global Impression–Severity of Suicidality–revised score; the between-group difference was not statistically significant. The most common adverse events among esketamine-treated patients were dizziness, dissociation, nausea, dysgeusia, somnolence, headache, and paresthesia. Conclusion: This study confirmed rapid and robust reduction of depressive symptoms with esketamine nasal spray in severely ill patients with MDD who have active suicidal ideation with intent. Trial Registration: Clinical Trials.gov identifier: NCT03097133
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Least-square mean changes (±SE) from baseline for Montgomery-Asberg Depression Rating Scale (MADRS) total score during the double-blind treatment phase (mixed-effects model using repeated measures [MMRM]; observed cases). aIncludes patients who had their dose reduced due to tolerability issues. Note: Negative change in score indicates improvement.](https://figures.cochat.ai/paper-figures/867338dabcaf42aca05b1ca83661094a/esketamine-nasal-spray-for-rapid-reduction-of-depressive-symptoms-in-patients-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“With regard to esketamine in particular, clinical use was largely based on four positive Phase 3 efficacy studies [62][63][64][65] that informed the subsequent FDA approval of intranasal esketamine for TRD and suicidal ideation with intent, as described above.”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“a nasal spray form of S-ketamine was approved by the Food and Drug Administration (FDA) in the USA and by the European Medicines Agency (EMA) in Europe in 2019 [18].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
Risk factors for suicide in psychiatric outpatients: A 20-year prospective study.
Brown, G. K., Beck, A. T., Steer, R. A., & Grisham, J. R. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.3.371 · Cited by 1,317 · cited 1×
“Nearly all patients with MDD who attempt or complete suicide have suicidal ideation prior to the event (Brown et al., 2000; Sokero et al., 2003).”
BackgroundValidity and Reliability of the Observer??s: Assessment of Alertness/Sedation Scale
CHERNIK, D. A., GILLINGS, D., LAINE, H., HENDLER, J., SILVER, J. M., DAVIDSON, A. B., SCHWAM, E. M., & SIEGEL, J. L. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199008000-00003 · Cited by 1,246
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Self-citationWilliams, J. B. W., & Kobak, K. A. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.032532 · Cited by 463 · cited 1×
“Eligible patients were between 18 and 64 years of age, met the Diagnostic and Statistical Manual of Mental Disorders–5th edition (DSM-5) criteria (American Psychiatric Association, 2013) for MDD (without psychosis) based on diagnostic assessment with the Mini International Neuropsychiatric Interview, and had a MADRS (…”
MethodPractice Guideline for the Assessment and Treatment of Patients With Suicidal Behaviors
(2007) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.56008 · Cited by 406
The European Psychiatric Association (EPA) guidance on suicide treatment and prevention
Wasserman, D., Rihmer, Z., Rujescu, D., Sarchiapone, M., Sokolowski, M., Titelman, D., Zalsman, G., Zemishlany, Z., & Carli, V. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.06.003 · Cited by 390 · cited 3×
“Current standard of care includes initiation or optimization of oral antidepressants and, frequently, hospitalization (American Psychiatric Association, 2003; Wasserman et al., 2012).”
Background
Research works printed but not linked: 1
- Spravato (esketamine) nasal spray. Prescribing information. 2020. Janssen Pharmaceutical Companies.
Cited by
Items 201–300 of 418
Kétamine et suicidalité : modèles animaux pour comprendre son mécanisme d’action
Nguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2023.10.008 · Cited by 2
Ketamin und Esketamin: Antidepressive pharmakologische Effekte und augmentierte Psychotherapie
Schüle, C., Koller, G., & Herwig, U. (2024) · Nervenheilkunde · doi:10.1055/a-2309-6457 · Cited by 1
Suicide and suicidal behaviors: insight into clinical challenges and preventive measures
Pompili, M., Berardis, D. D., Dell’Osso, B. M., Forte, A. M., Innamorati, M., Rogante, E., Sarli, G., Serafini, G., & Amore, M. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2542764 · Cited by 4
“The ASPIRE trials [165,166] showed that esketamine combined with a comprehensive Standard of Care (SOC) rapidly reduced depressive symptoms in MDD patients with acute suicidal ideation or behavior, especially in those with a history of suicide attempts.”
Spravato oder die Frage: „Wie viel darf ein Antidepressivum kosten?“
Spießl, H. (2021) · Psychiatrische Praxis · doi:10.1055/a-1500-9805 · Cited by 1
Ketamine and Other Glutamate Receptor Antagonists As Fast-Actin
Chen, M., Su, T., & Tsai, S. (2022) · Neuromethods · doi:10.1007/978-1-0716-2083-0_19 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.083 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.018 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.032 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.017 · Cited by 2
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.086 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.046 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.055 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.071 · Cited by 1
Wilkowska, A., & Cubała, W. J. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01222-x · Cited by 1
Plöderl, M., Cooper, R. E., Walker, T., Shah, V., Horowitz, M. A., Volkmann, C., & Moncrieff, J. (2025) · medRxiv · doi:10.1101/2025.08.19.25333796 · Cited by 2
Diekamp, B., Borentain, S., Fu, D., Murray, R., Heerlein, K., Zhang, Q., Schüle, C., & Mathews, M. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.09.546
Self-citationStahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.009
The high-pressure structures and properties of τ-Zr(HPO4)2Preprint
Andersen, A. M. K., & Carlson, S. (2004)
À propos de l’utilisation du traitement de la kétamine aux urgences psychiatriques
Sergentanis, I. N., Vibert, V., Costanza, A., Néris, M. D., Besson, M. J., Kosel, M., Bondolfi, G., & Ambrosetti, J. (2021) · JMIG · doi:10.53738/revmed.2021.17.725.0303 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.058
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.051
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.007
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.045 · Cited by 2
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.008
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.097
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.082
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.074
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.093
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.028
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.026
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.029
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.035
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.015
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.044
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.001
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.034
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.089
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.016
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.049
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.061
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.048
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.019
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.066
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.052 · Cited by 1
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.031
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.014
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.075
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.043
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.077
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.063
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.064
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.081
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.078
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.054
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.037
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.021
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.090
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.062
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.020
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.088
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.070
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.011
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.080
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.095
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.094
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.073
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.098
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.012
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.027
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.036
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.085
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.087
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.040
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.076
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.010
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.069
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.060
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.072
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.050
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.053
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.033
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.059
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.056
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.096
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.099
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.025
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.022
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.030
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.023
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.068
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.041
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.092
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.004
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.067
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.039
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.047
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.065
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.084
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.002
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.057
Metadata
- Authors
- Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M.
- Affiliations
- Department of Neuroscience, Janssen Research and Development, LLC, San Diego, CA
- Janssen Research & Development (United States) (US)
- Medical University of Vienna (AT)
- Corresponding author
- Ionescu, Dawn F
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-29
- Volume
- 24
- Issue
- 1
- Pages
- 22-31
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7816667
- OpenAlex
- W3082490768
- Cited by
- 418
- References
- 28
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 41 · 2023: 49 · 2022: 43 · 2021: 31 · 2020: 161
- FWCI
- 42.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Keywords
- esketamine, nasal spray, major depressive disorder, rapid-acting antidepressants, depressive symptoms, suicidality, hospitalization, adverse events, dissociation
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Outcome Assessment, Health Care, Young Adult, Suicidal Ideation, Nasal Sprays, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.